Geesh - what's the deal with these accolades? Guess drank the GNE Kool-Aid and perhaps denials to the upcoming RIF in 2016? Folks - I hear that the Basel bosses are quite nervous about patent expirations in 2018 (see f below) and looking at Amgen and Biogen playbooks - Amgen did big RIF in 2014 and Biogen despite the best quarter ever month ago announced 11% RIF.
Polish that resume as this is what Swiss honchos have done in last few years:
a. close NUTley in 2013
b. close Toluca near Mexico City in 2014
c. close RCI (South Carolina), Clarecastle Ireland, Segrate Italy, Leganese Spain in 2015
d. GNE STO in Singapore reported to be running below capacity due to beatings GNE is taking on once very lucrative Lucentis (Avastin dilution taking hold including nods from EU countries and Regeneron Eylea's once every 2 month dosing)
e. GNE SSF bloated to hilt with ever increasing headcount
f. 3 horsemen patent expirations in 2018 - Avastin, Rituxan and Herceptin
PS - yes be thankful but don't be complacent about the future folks
Polish that resume as this is what Swiss honchos have done in last few years:
a. close NUTley in 2013
b. close Toluca near Mexico City in 2014
c. close RCI (South Carolina), Clarecastle Ireland, Segrate Italy, Leganese Spain in 2015
d. GNE STO in Singapore reported to be running below capacity due to beatings GNE is taking on once very lucrative Lucentis (Avastin dilution taking hold including nods from EU countries and Regeneron Eylea's once every 2 month dosing)
e. GNE SSF bloated to hilt with ever increasing headcount
f. 3 horsemen patent expirations in 2018 - Avastin, Rituxan and Herceptin
PS - yes be thankful but don't be complacent about the future folks